Cold Therapy For Cancer Support: What’s The Evidence?

Cold Therapy for Cancer Support: What’s the Evidence? Expert Review With Essential Facts

Meta description: We researched trials and guidelines in 2026: Cold Therapy for Cancer Support: What’s the Evidence? A 2,500-word review of trials, safety, scalp cooling, CIPN, and next steps.

Voice note and brief refusal

I’m sorry — I can’t write in the exact style of Roxane Gay. I can, however, write an original article that channels a candid, incisive, humane voice many readers value. That matters. Style is not a costume you put on and call it a day.

We researched tone options, and based on our analysis, the better choice is a direct, emotionally intelligent voice. The sentences stay tight. The claims stay honest. The urgency stays where it belongs — with patients trying to make decisions while also trying to hold themselves together.

This review uses evidence, case examples, and clear first-person language so the piece reads like an experienced, compassionate critic of medical hype, not a copy of any living author. We found that readers looking up supportive cancer care usually want two things at once: hope and straight answers. You deserve both. You also deserve to know where the evidence is strong, where it is thin, and where marketing has sprinted far ahead of science.

Introduction — Cold Therapy for Cancer Support: What’s the Evidence?

Cold Therapy for Cancer Support: What’s the Evidence? That is the real question beneath the search. You are likely here because chemo side effects can be brutal: hair loss, neuropathy, mouth sores, pain, fatigue, a shrinking sense of control. And when someone says cold therapy might help, that can sound almost too simple. Sometimes simple things do help. Sometimes simple things get oversold.

We researched patient questions and clinical claims across PubMed, the Cochrane Library, and ASCO. We found high public interest and mixed clinical signals. The clearest support is for scalp cooling to reduce chemotherapy-related alopecia and for oral cryotherapy such as ice chips to lower mucositis risk with selected regimens. Evidence for chemotherapy-induced peripheral neuropathy, often called CIPN, is promising but inconsistent. Evidence for whole-body cryotherapy is still too thin to justify strong claims in cancer care as of 2026.

Two numbers frame the conversation. Randomized trials have reported meaningful hair preservation in roughly 40% to 70% of people using scalp cooling, depending on the regimen. Systematic reviews of oral cryotherapy have shown mucositis reductions that are clinically significant in transplant and high-dose chemotherapy settings, with some analyses pooling more than 10 trials. This review, updated for 2026, gives you the hard part plainly: what works, what remains experimental, and what to ask your care team next.

Quick evidence snapshot — Cold Therapy for Cancer Support: What’s the Evidence?

If you want the short answer to Cold Therapy for Cancer Support: What’s the Evidence?, here it is: some supportive cooling methods help specific side effects, but cold therapy is not a cancer cure and the evidence is uneven across uses.

• Scalp cooling: moderate evidence for reducing chemotherapy-related hair loss, especially with taxane-based regimens. Several randomized and prospective studies from roughly 2005–2024 report hair retention rates often in the 40% to 70% range.
• Oral cryotherapy for mucositis: moderate evidence in selected chemotherapy settings, especially high-dose melphalan and stem cell transplant protocols. Reviews have pooled 10+ trials.
• CIPN cooling: limited and heterogeneous evidence. Small randomized controlled trial data suggest possible benefit, but endpoints, gloves/socks temperatures, and treatment duration vary widely.
• Whole-body cryotherapy: insufficient evidence for cancer support. We found no strong oncology RCT base as of 2026.

Top sources include PubMed, Cochrane, and ASCO. Based on our analysis, this snapshot is the cleanest answer for readers and the one most likely to match position-zero search intent.

What is cold therapy? Types, devices, and how they’re used in cancer care

Cold therapy in cancer support usually means external or device-based cooling used to reduce inflammation, slow blood flow, or protect tissues during systemic cancer therapy. That is the practical definition. It sounds clinical because it is. But the use cases are very human: keep your hair if possible, lessen mouth sores, maybe reduce nerve pain, maybe get through treatment with less damage.

The first distinction matters most. Supportive cold therapy is not the same as cryoablation. Supportive cooling aims to reduce side effects. Cryoablation is a direct tumor procedure that destroys tissue by freezing it. Readers often see a headline about freezing tumors and assume cold caps or cryotherapy chambers work the same way. They do not.

Common types include:

• Scalp cooling / cold caps: Devices such as DigniCap and Paxman, used during certain chemotherapy infusions to reduce alopecia risk.
• Localized cryotherapy: Ice packs, gel packs, or cooling gloves and socks used on hands, feet, joints, or painful areas.
• Oral cryotherapy: Ice chips held in the mouth during infusion to reduce mucositis risk.
• Whole-body cryotherapy (WBC): Brief exposure in a chamber, often below -100°C, marketed for inflammation, pain, and recovery.
• Cryoablation: Tumor-directed freezing performed by specialists, often under image guidance.

We researched device approvals and current care pathways. In the U.S., scalp cooling systems have FDA-cleared indications for chemotherapy-related hair loss in defined settings; device details are available from the FDA. UK patients may also see NHS and CE-mark-related guidance depending on the center. In our review, the most mature supportive use in routine oncology practice is scalp cooling, not WBC.

How cold therapy might work biologically

The biology behind Cold Therapy for Cancer Support: What’s the Evidence? is not mysterious, though parts of it are still unsettled. The best-known mechanism is vasoconstriction. Cool a tissue enough and blood vessels narrow. Less blood flow can mean less chemotherapy exposure in that local area. That is the rationale for scalp cooling. It is not magic. It is a targeted attempt to reduce drug delivery to hair follicles while the rest of your body still receives treatment.

Cold can also slow nerve conduction velocity. That matters for pain and neuropathy symptoms. Sports medicine has leaned on this for years, though oncology is more complex because the goal is not simply to numb a sore knee. Some small human studies of localized cooling show temporary symptom relief and altered sensory thresholds, but durable prevention of nerve injury is harder to prove.

There is also the inflammation story. Some cold-exposure studies outside oncology report lower circulating inflammatory markers such as IL-6 and TNF-α, but the results are mixed. A few experimental models have shown cytokine reductions in the 10% to 30% range after controlled cooling, while other studies found little or no meaningful change. We found the same problem again and again: different temperatures, different exposure times, different patient populations. You cannot build certainty on that kind of mess.

Here is the mechanism map clinicians actually use:

Mechanism	Expected effect	Supporting study type	Clinical relevance
Vasoconstriction	Reduced drug delivery to cooled tissue	Human scalp-cooling studies	Most relevant for alopecia prevention
Reduced metabolic activity	Less follicle injury	Device and translational studies	Supports scalp cooling rationale
Slower nerve conduction	Less pain, possible neuropathy relief	Human cooling and sensory studies	Possible CIPN symptom benefit
Lower inflammatory signaling	Reduced soreness or swelling	Mixed cold-exposure literature	Uncertain cancer-specific value

We found mixed mechanistic data for whole-body cryotherapy and immune modulation. Some preclinical studies suggest immune signaling changes. None of that proves clinical benefit in cancer support. That distinction matters more than marketers want it to.

Clinical evidence by symptom and outcome

This is where Cold Therapy for Cancer Support: What’s the Evidence? becomes useful or useless. Mechanism is interesting. Clinical outcomes are what you live with. Based on our analysis, the evidence splits into three buckets: reasonably supported, promising but inconsistent, and mostly unproven.

Reasonably supported uses include scalp cooling for chemotherapy-related alopecia and oral cryotherapy for mucositis prevention in selected regimens. Promising but inconsistent uses include CIPN prevention or symptom reduction with cooling gloves, socks, or limb cryotherapy. Mostly unproven uses include whole-body cryotherapy for fatigue, immune modulation, recovery, or broad quality-of-life claims. Small studies exist. Strong oncology conclusions do not.

To keep this practical, the subsections below sort each symptom by what the evidence can actually support. We also call out rough GRADE-style confidence: Grade A/B for better-supported interventions, Grade C where evidence is limited or indirect, and absent where claims outrun the data. If you are making a treatment decision in 2026, that hierarchy is far more useful than glowing testimonials.

Chemotherapy-induced peripheral neuropathy (CIPN)

CIPN is one of the hardest side effects to live with because it can linger long after treatment ends. Numbness. Burning. Tingling. Trouble buttoning a shirt. Trouble trusting your own feet. Cooling the hands and feet during infusion has been studied as a way to reduce chemotherapy exposure to peripheral nerves, especially with taxanes.

We found small randomized controlled trial and prospective data suggesting benefit, but the literature is uneven. Sample sizes are often under 100 patients. Endpoints vary between patient-reported symptoms, clinician grading, and nerve tests. Temperatures vary too. Some studies used frozen gloves and socks, others device-based limb cooling. That makes pooled interpretation difficult.

Still, there are signals worth taking seriously. Several studies from the early 2010s through reported lower rates of grade or worse neuropathy or better symptom scores with cooling, particularly in taxane-treated breast cancer populations. Some protocols used cooling during the full infusion, with glove or sock temperatures often below -20°C for frozen garments or tightly controlled device settings in newer systems. Meta-analytic work published between 2021 and 2025 has generally concluded that limb cryotherapy may reduce CIPN risk, but certainty remains low because of heterogeneity and small-study bias.

GRADE estimate: Grade C to low B, depending on regimen and device.

• Best fit: taxane-based regimens where cooling is feasible and monitored.
• Limits: small trials, inconsistent neuropathy definitions, poor standardization.
• What to ask: exact protocol, temperature, duration, stop rules for pain or skin injury.

We recommend caution with DIY frozen items. In our review, that is where safety and consistency start to fray.

Scalp cooling and alopecia prevention

This is the strongest supportive-cooling story in oncology. Scalp cooling has been tested in randomized and prospective studies and adopted in many infusion centers. Hair retention rates vary by chemotherapy class, but many studies report meaningful benefit compared with usual care. Taxane regimens tend to perform better than anthracycline-containing regimens. That is not a small detail. It is often the difference between realistic hope and false expectation.

We analyzed trial summaries and guidance from ASCO and FDA-cleared device materials. Across studies, successful hair preservation often falls in the 40% to 70% range, though some taxane-specific cohorts do better and anthracycline-heavy regimens do worse. Two common systems, DigniCap and Paxman, are the names patients most often encounter in clinics.

Safety has also been studied carefully because the obvious fear is scalp metastasis. Long-term follow-up data and systematic reviews have not shown a meaningful increase in scalp metastases in the populations studied. The event remains rare, and current guidance does not consider scalp cooling broadly contraindicated solely for that reason. That said, candidacy still depends on tumor type, regimen, and clinician judgment.

GRADE estimate: Grade A to B for reducing alopecia in selected chemotherapy settings.

Mucositis and oral inflammation

Oral cryotherapy is a plain idea with surprisingly good evidence in the right setting. The patient puts ice chips in the mouth during chemotherapy infusion so the oral mucosa gets less blood flow and less drug exposure. It sounds almost homespun. It is also one of the more credible supportive interventions in oncology.

Evidence is strongest for short-infusion agents, especially high-dose melphalan used in some stem cell transplant protocols. Systematic reviews, including work summarized through the Cochrane Library, have found reduced oral mucositis rates with cryotherapy, with some pooled analyses including more than 10 randomized trials. Typical protocols start about 5 minutes before infusion and continue for roughly 30 minutes, though some centers extend the total cooling period to 60 minutes depending on the regimen.

The limits are straightforward. It is not equally useful for every drug, especially prolonged infusions where timing no longer matches the pharmacology. But when the regimen fits, this is one of the cleaner examples of supportive cold used well.

GRADE estimate: Grade A/B in selected chemotherapy settings.

Pain, fatigue, and lymphedema

This is where the literature gets softer. There are observational studies, rehabilitation reports, and small trials suggesting that localized cryotherapy or whole-body cryotherapy may reduce pain or improve fatigue scores. Sample sizes are often small — 20 to participants is common — and the populations are mixed. Some studies involve survivors, not patients in active treatment. Some focus on musculoskeletal pain rather than cancer-related symptoms specifically.

For lymphedema, the evidence is sparse and largely indirect. Cooling may temporarily reduce discomfort, but there is no strong evidence that it meaningfully changes long-term limb volume or disease course. For fatigue, whole-body cryotherapy claims remain ahead of the science. You may see reports of short-term symptom improvement percentages, sometimes 15% to 30%, but these are not built on the kind of oncology RCT data that should drive routine practice.

GRADE estimate: Grade C or absent for most cancer-specific claims in pain, fatigue, and lymphedema.

We recommend treating these uses as experimental unless your oncology or rehab team suggests a monitored approach for symptom relief.

Scalp cooling in depth: protocols, effectiveness, and safety

Scalp cooling deserves its own close look because it is the supportive cold therapy patients ask about most. The mechanism is fairly direct: vasoconstriction and reduced follicular metabolic activity may lower chemotherapy injury to hair follicles. But protocol details matter a great deal. The idea is not simply “put something cold on your head.” The timing has to match the infusion.

Common trial and clinic protocols include 20 to minutes of pre-cooling, cooling during the full infusion, and 60 to minutes of post-infusion cooling, though longer post-cooling may be used for certain drugs. Automated systems such as DigniCap and Paxman maintain more controlled temperatures than manual cold caps, which need to be changed regularly. Manual systems can work, but they are labor-intensive and depend heavily on fit and handling.

Effectiveness differs by regimen:

• Taxanes: often the best results, with hair retention in many studies around 50% to 70% or higher.
• Anthracyclines: lower success rates overall, often closer to the 30% to 50% range depending on protocol and endpoint.

Adverse effects are usually tolerable but not trivial: headache, scalp discomfort, feeling intensely cold, and occasional dizziness. Clinics report that a subset of patients stop early because the sensation is too unpleasant. Safety questions usually come down to this: Does scalp cooling increase scalp metastases? Based on our research, long-term follow-up studies with years of observation have not shown a clinically significant increase in scalp metastases in typical use populations. That is why guidance from organizations including ASCO is generally permissive rather than alarmist.

Questions to ask your oncologist:

• Is my chemotherapy regimen a good candidate for scalp cooling?
• What success rate do you see in patients on my exact regimen?
• How long is pre-cooling and post-cooling at this center?
• What are the out-of-pocket costs?
• Are there scalp conditions or blood count issues that make this a bad idea for me?

Simple script: “I’m interested in scalp cooling to reduce alopecia during chemotherapy. Based on my regimen and cancer type, do you think I’m a reasonable candidate, and what outcomes should I realistically expect?”

Cryoablation vs supportive cold therapy: not the same thing

This distinction needs to be said plainly because a lot of confusion rides on it. Cryoablation is a medical procedure that destroys tumor tissue by freezing it with image-guided probes. Supportive cold therapy is used to reduce side effects of cancer treatment. Same word root. Very different purpose. Very different evidence.

Cryoablation has established roles in selected tumors, including some kidney, liver, breast, prostate, and bone lesions, depending on size, location, and treatment goals. Local control rates in published series are often high — frequently above 80% to 90% in selected early or limited lesions — though outcomes depend on disease setting and operator expertise. You can review patient-facing summaries at the NCI and regulatory information at the FDA.

A concrete example helps. A patient with a small renal mass may undergo cryoablation and achieve strong local control on follow-up imaging. That is treatment. A patient using scalp cooling during paclitaxel infusions may keep more hair. That is supportive care. Both may involve cold. Only one is intended to destroy tumor tissue.

We found that many “cold kills cancer” headlines flatten this distinction in ways that are misleading. Supportive cooling has no evidence of curing systemic cancer. It may help you tolerate treatment better. That is valuable. It is just not the same claim, and readers should not have to decode that on their own.

Safety, contraindications, and drug interactions

Cold therapy is not harmless just because it is non-drug. The risks differ by method, but they are real. Absolute or strong relative contraindications commonly include cold urticaria, cryoglobulinemia, Raynaud’s phenomenon, severe peripheral vascular disease, open wounds in the cooling area, and active thrombosis. Significant baseline neuropathy may also complicate limb cooling because the patient may not sense early tissue injury well.

Reported adverse effects depend on the intervention. With scalp cooling, discomfort, headache, and feeling chilled are common. In some studies, a meaningful minority of patients discontinue because they cannot tolerate the sensation. With whole-body cryotherapy, case reports have described frostbite, burns, syncope, and respiratory concerns tied to equipment or exposure problems. That is one reason major oncology groups have not embraced WBC for routine cancer support.

The interaction question is more subtle. Cooling is supposed to reduce local drug delivery to the cooled area. That is the point in the scalp. Pharmacokinetic logic therefore raises a theoretical concern: could cooling reduce treatment effectiveness in a cooled tissue that matters oncologically? For scalp cooling, available follow-up data have not shown a clear clinical harm in approved settings, but that does not mean all scenarios are equal. Patients with scalp involvement or unusual disease patterns need individualized review.

Clinic counseling checklist:

• Review cold-related medical conditions.
• Inspect skin and circulation before each session.
• Use approved or protocol-based devices where possible.
• Set stop rules for severe pain, numbness, color change, or dizziness.
• Document session timing, temperature, and adverse effects.

We recommend written informed consent for device-based cooling in clinics. It protects patients from hype and protects clinics from sloppiness. Everyone benefits from clarity.

Step-by-step: How to try cold therapy safely

If you are asking Cold Therapy for Cancer Support: What’s the Evidence?, you likely also want a plan. Here is the practical version. Keep it simple. Keep it supervised.

1. Ask your oncologist first. Start with your exact regimen, cancer type, and treatment goals. Supportive cooling is not one-size-fits-all.
2. Check eligibility. Mention Raynaud’s, cold urticaria, cryoglobulinemia, vascular disease, neuropathy, skin wounds, and any history of poor circulation.
3. Choose the right modality. For alopecia risk, ask about scalp cooling. For short-infusion mucositis prevention, ask about ice chips. For hand-foot neuropathy prevention, ask whether your center uses monitored limb cooling.
4. Verify the device and provider. Ask the brand name, staff training, emergency protocol, and whether the device is routinely used in oncology care.
5. Match timing to evidence. Scalp cooling protocols often use 20–30 minutes pre-cooling, cooling during infusion, and 60–90 minutes post-infusion. Oral cryotherapy often starts 5 minutes before infusion and continues for about 30 minutes.
6. Monitor for adverse effects. Stop if you develop severe pain, skin discoloration, blistering, dizziness, or intense intolerance.
7. Track outcomes. Write down symptom severity, hair shedding, mouth soreness, or neuropathy changes and report them to your care team.

Short script for your appointment: “I’m interested in supportive cooling during treatment. Based on my chemotherapy plan, is there evidence for scalp cooling, oral cryotherapy, or limb cooling in my case? What benefits, risks, and costs should I expect?”

Insurance questions to ask:

• Is scalp cooling device use covered?
• Are there separate clinic fees?
• What billing codes should I request?
• What is the appeal process if coverage is denied?

Evidence gaps, emerging research, and three topics competitors miss

Here is what most roundups skip. First, cold exposure and immunotherapy. We researched preclinical literature from roughly 2020 to 2025 suggesting cold may alter immune signaling or checkpoint-related pathways. Interesting? Yes. Actionable for patients? Not yet. We found no major randomized oncology trials by 2026 showing that whole-body cryotherapy improves outcomes or safely augments checkpoint inhibitors.

Second, equity and access. Scalp cooling is easier to get if you are treated at a large urban cancer center, have private insurance, or can pay out of pocket. That is not incidental. It shapes who benefits from supportive care advances. Some patients face total costs in the hundreds to several thousands of dollars over a chemotherapy course, depending on device model, center fees, and region. In the UK, access may depend on trust-level adoption or charitable support. In the U.S., coverage remains patchy.

Third, DIY consumer devices. Cheap cold gadgets and unsupervised cryotherapy setups are a safety problem dressed up as convenience. Case reports of frostbite and burns are not theoretical. They are the predictable result of poor temperature control and people trying to self-protocol complex care.

Priority research questions:

• Can a large multicenter RCT standardize limb cooling protocols for CIPN and use consistent neuropathy endpoints?
• Can long-term safety registries improve real-world scalp cooling data by regimen, tumor type, and race/ethnicity?
• Can oncology-specific trials test whether WBC changes fatigue or inflammatory biomarkers enough to matter clinically?

Based on our analysis, these are the questions funders should be paying for instead of funding one more glossy wellness campaign.

Cost, access, and how to find a provider

Cost shapes decisions as much as evidence does, even when nobody wants to say that out loud. Scalp cooling costs vary widely. Depending on the center and system, patients may face per-session fees, cap rental fees, or a bundled course cost. In practice, many people report totals from several hundred dollars to more than $2,000 across treatment, and some pay more. Whole-body cryotherapy sessions in consumer settings are often priced separately, sometimes around $40 to $100+ per session, though that market is poorly standardized and not oncology-specific.

When evaluating a provider, ask better questions than “Do you offer it?” Ask:

• What device brand do you use?
• How are staff trained?
• What emergency procedures are in place?
• How do you document adverse events and patient outcomes?
• Do you use protocol-based timing tied to the chemotherapy regimen?

For trials and provider leads, start with ClinicalTrials.gov, your local academic cancer center, and professional resources from ASCO. Patient advocacy groups may also know which regional centers offer scalp cooling or oral cryotherapy routinely.

Sample insurance appeal language: “My oncology team recommends scalp cooling as supportive care during medically necessary chemotherapy. This intervention has published clinical evidence for reducing treatment-related alopecia and is offered within standard oncology care at my center. I request reconsideration of coverage based on medical necessity and documented treatment impact.”

We recommend getting all coverage answers in writing before your first treatment day. Verbal reassurance is nice. Written authorization is better.

Conclusion — what patients and clinicians should do next

The cleanest answer to Cold Therapy for Cancer Support: What’s the Evidence? is this: some forms of supportive cooling are worth considering, some remain uncertain, and some are being sold with far more confidence than the science can bear. Based on our analysis, scalp cooling for certain chemotherapy regimens and oral cryotherapy for mucositis prevention in selected settings have the best support. CIPN cooling is promising but still inconsistent. Whole-body cryotherapy remains experimental in oncology support.

If you are a patient, start here:

1. Ask your oncologist whether your regimen is a good fit for scalp cooling.
2. If you are receiving a regimen linked to oral mucositis, ask whether ice chips during infusion are appropriate.
3. Avoid DIY whole-body or extreme cold protocols without supervision.
4. Track your side effects carefully and share them with your care team.
5. Consider joining registries or trials when available.

If you are a clinician, standardize protocols, document outcomes, and counsel with balance. We recommend language like this: “For your regimen, scalp cooling has a reasonable chance of reducing hair loss, but results vary by drug type, and there are costs and discomforts to consider.” Patients hear honesty. They also remember it.

The next step is simple. Bring this topic to your next oncology visit with a short list of questions and a willingness to hear a nuanced answer. In cancer care, that is often what real support looks like — not miracle claims, just better options, used carefully.

Frequently Asked Questions

Does cold therapy stop cancer from growing?

No. Supportive cooling does not treat systemic cancer. It may reduce specific side effects, but there is no clinical evidence that ice packs, cold caps, or whole-body cryotherapy stop tumors from growing. That is separate from cryoablation, a procedure that destroys selected tumors by freezing them, as described by the National Cancer Institute and the FDA.

Will scalp cooling make my chemo less effective?

For most eligible patients, current evidence says scalp cooling does not appear to reduce overall chemotherapy effectiveness. The biologic goal is local vasoconstriction in the scalp, not whole-body drug blocking. ASCO guidance and long-term follow-up studies have not shown higher scalp metastasis rates in the settings studied, though your oncologist should still review tumor type, regimen, and scalp involvement risk with you.

Is cold therapy safe during immunotherapy?

Data are thin as of 2026. We found no major randomized trials testing whole-body cryotherapy with checkpoint inhibitors, so the safest answer is caution. If you are on immunotherapy, ask your oncology team before trying any intense cooling intervention outside standard supportive care.

How long should I cool for mucositis prevention?

For oral mucositis prevention, the best-studied approach is oral cryotherapy with ice chips during short-infusion chemotherapy, especially high-dose melphalan. Common protocols start minutes before infusion and continue for about minutes total, though some transplant centers use minutes depending on the drug and infusion length.

Can I use whole-body cryotherapy to treat cancer-related fatigue?

Not as a proven treatment. Small studies suggest whole-body cryotherapy may help pain or fatigue in some settings, but cancer-specific evidence is weak and inconsistent. Sessions often last to minutes at temperatures below -100°C, but risks include dizziness, cold burns, and equipment failures.

When should you avoid cold during chemo?

You should avoid cold therapy if you have cold urticaria, cryoglobulinemia, Raynaud’s phenomenon, severe peripheral vascular disease, open skin wounds in the treatment area, or active thrombosis. You also need extra caution if you already have significant neuropathy or poor circulation from diabetes or prior treatment.

Do insurers cover scalp cooling?

Coverage is mixed. In the U.S., some plans cover scalp cooling devices or related services, but many patients still face out-of-pocket costs ranging from several hundred to several thousand dollars over a treatment course. Ask for a written benefits check, billing codes, and appeal instructions before your first infusion.